Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer

Cancer Letters

Volumn 189, Issue 1, 2003, Pages 97-102

  Toyama, Tatsuya ^a   Iwase, Hirotaka ^a   Yamashita, Hiroko ^a   Hara, Yasuo ^a   Omoto, Yoko ^a   Sugiura, Hiroshi ^a   Zhang, Zhenhuan ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

Breast cancer; Metastasis; Syk; Tumor suppressor gene

Indexed keywords

PROTEIN; PROTEIN KINASE SYK; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER PATIENT; CANCER RISK; CANCER TISSUE; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE EXPRESSION; GENE FUNCTION; HEMATOPOIETIC CELL; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; ENZYME PRECURSORS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM METASTASIS; PROGNOSIS; PROTEIN-TYROSINE KINASES;

EID: 0037427571     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00463-9     Document Type: Article

References (13)

1. Yanagi S., Inatome R., Takano T., Yamamura H. Syk expression and novel function in a wide variety of tissues. Biochem. Biophys. Res. Commun. 288:2001;495-498.
2. Sada K., Takano T., Yanagi S., Yamamura H. Structure and function of Syk protein-tyrosine kinase. J. Biochem. 130:2001;177-186.
3. Kurosaki T. Molecular mechanisms in B cell antigen receptor signaling. Curr. Opin. Immunol. 9:1997;309-318.
4. Chu D.H., Morita C.T., Weiss A. The Syk family of protein tyrosine kinases in T-cell activation and development. Immunol. Rev. 165:1998;167-180.
5. Fluck M., Zurcher G., Andres A.C., Ziemiecki A. Molecular characterization of the murine syk protein tyrosine kinase cDNA, transcripts and protein. Biochem. Biophys. Res. Commun. 213:1995;273-281.
6. Coopman P.J., Do M.T., Barth M., Bowden E.T., Hayes A.J., Basyuk E., Blancato J.K., Vezza P.R., McLeskey S.W., Mangeat P.H., Mueller S.C. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature. 406:2000;742-747.
7. Yuan Y., Mendez R., Sahin A., Dai J.L. Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Res. 61:2001;5558-5561.
8. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 19:1991;403-410.
9. Toyama T., Iwase H., Watson P., Muzik H., Saettler E., Magliocco A., DiFrancesco L., Forsyth P., Garkavtsev I., Kobayashi S., Riabowol K. Suppression of ING1 expression in sporadic breast cancer. Oncogene. 18:1999;5187-5193.
10. Shi S.R., Key M.E., Kalra K.L. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J. Histochem. Cytochem. 39:1991;741-748.
11. Baselga J., Averbuch S.D. ZD1839 ('Iressa') as an anticancer agent. Drugs. 60:(Suppl. 1):2000;33-40.
12. Ciardiello F., Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 7:2001;2958-2970.
13. Sirotnak F.M., Zakowski M.F., Miller V.A., Scher H.I., Kris M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6:2000;4885-4892.